Biomarkers, Communications Are Key To Accelerating R&D, FDA Says

Genentech's Herceptin is a good example of how the tradeoffs in targeted drug development can work out medically and commercially, FDA Commissioner McClellan told an IBC meeting in Boston Aug. 12